Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2022-02-24 Board/Management Inform…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Company Secretary Change
Board/Management Information Classification · 1% confidence The document is a short announcement disseminated via RNS (Regulatory News Service) from Arix Bioscience Plc. The core content announces the 'Appointment of Company Secretary' (Derringtons Limited). This type of announcement, dealing with changes in key administrative roles or governance personnel, fits best under Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is more precise than the general 'RNS' fallback category. The document length is short (2095 chars), but it is the primary announcement itself, not an announcement *about* another report, so the RPA rule does not strictly apply here to override the content classification.
2022-02-24 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces the 'Total Voting Rights' as of a specific date (7 February 2022) and provides the total number of issued shares and the number of shares with voting rights. This information is crucial for shareholders calculating their notification obligations under Disclosure Guidance and Transparency Rules. This content directly relates to the capital structure and voting rights calculation, which aligns best with the 'Major Shareholding Notification' (MRQ) definition, as the announcement states the figure 'may be used by shareholders for the calculations by which they will determine if they are required to notify their major interest...'. While it is a regulatory announcement, MRQ is more specific than the general RNS, as it deals directly with shareholding thresholds.
2022-02-08 English
Arix Bioscience PLC: Clinical development update from portfolio company LogicBio
Regulatory Filings Classification · 1% confidence The document is an announcement released by Arix Bioscience PLC concerning an update from its portfolio company, LogicBio Therapeutics, regarding a clinical hold placed by the FDA on the LB-001 trial. The text explicitly states it is a 'Regulatory Announcement' disseminated via EQS Group. It details specific clinical trial events (clinical hold, SAEs) and includes the full press release from the portfolio company. Since this is an announcement by an investor (Arix) about a material event concerning an investment, and it is not a full periodic report (like 10-K or IR), nor a standard earnings release (ER), it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory disclosure, or potentially a Legal/Regulatory update, but RNS is the most appropriate fallback for non-standard regulatory news dissemination.
2022-02-02 English
Notification of Major Share Holding
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'Notification of Major Share Holding' and contains the standardized form 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, crossing specific thresholds. This directly corresponds to the definition for Major Shareholding Notification (MRQ). The document details the shareholder, the date the threshold was crossed (7 January 2022), and the resulting percentage of voting rights (20.541513%).
2022-01-11 English
Arix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
Regulatory Filings Classification · 1% confidence The document is a short announcement dated December 22, 2021, detailing Arix Bioscience PLC's co-leading of a $31 million Series A financing round for a new portfolio company, Sorriso Pharmaceuticals. It describes the investment amount, the resulting ownership stake, and the intended use of funds. This type of announcement, concerning fundraising, financing activities, or capital structure changes, directly matches the definition for 'Capital/Financing Update'. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific corporate finance event.
2021-12-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is explicitly labeled with 'RNS Number' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This structure details share purchases by individuals identified as CEO, Non-Executive Director, and SID. This type of insider transaction reporting directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2021-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.